Trillium Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Trillium Therapeutics generated cash of -$22,733,000, which is more than the previous year. Cash used in financing activities reached the amount of $290,907,000 last year. Net change in cash is therefore $233,016,000.
Cash Flow
| 2011 | -1.85M | 21.48K | 1.64M |
|---|---|---|---|
| 2012 | -1.32M | 0 | 0 |
| 2013 | -2.33M | -542.74K | 32.06M |
| 2014 | -6.41M | 304.08K | 692.26K |
| 2015 | -13.18M | -540.74K | 53.06M |
| 2016 | -17.00M | -9.33M | 255.73K |
| 2017 | -21.50M | -45.69M | 49.76M |
| 2018 | -28.85M | 22.48M | -84.43K |
| 2019 | -24.90M | 10.12M | 13.50M |
| 2020 | -22.73M | -35.48M | 290.90M |
TRIL Cash Flow Statement (2011 – 2020)
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 14.58M | 15.31M | 20.82M | 40.13M | 64.55M | 18.85M | 27.95M | 1.29M | 2.71M | 2.82M |
Operating activities | ||||||||||
Net income | -59.34M | -41.62M | -31.19M | -35.85M | -23.60M | -10.61M | -11.09M | -4.02M | -1.06M | -3.10M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 591K | 2.10M | 2.30M | 3.74M | 3.18M | 329.85K | 566.80K | 609.32K | 6.41K | 250.35K |
Stock-based compensation expense | 36.45M | 1.60M | 1.84M | 2.58M | 2.74M | 1.95M | 1.99M | 299.48K | 34.68K | 326.30K |
| Deferred income tax benefit | 36.45M | 1.60M | 1.84M | 2.58M | 2.74M | 1.95M | 1.99M | 299.48K | 34.68K | 326.30K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | -432K | -142K | 485.17K | -630.40K | 82.81K | 554.91K | -119.59K | -21.27K |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 6.29M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by operating activities | -22.73M | -24.90M | -28.85M | -21.50M | -17.00M | -13.18M | -6.41M | -2.33M | -1.32M | -1.85M |
Investing activities | ||||||||||
Purchases Of Investments | -66.28M | 0 | 0 | -45.32M | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | -324K | -59.47K | -374.55K | -2.20M | -540.74K | -149.54K | -31.94K | 0 | 0 |
Acquisitions Net | 0 | 0 | 0 | 0 | -7.12M | 0 | 0 | -608.57K | 0 | 0 |
Cash generated by investing activities | -35.48M | 10.12M | 22.48M | -45.69M | -9.33M | -540.74K | 304.08K | -542.74K | 0 | 21.48K |
Financing activities | ||||||||||
Common Stock Issued | 0 | 8.51M | 0 | 49.86M | 267.33K | 52.98M | 832.49K | 31.95M | 0 | 1.64M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | -84.43K | 0 | -78.45K | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 290.90M | 13.50M | -84.43K | 49.76M | 255.73K | 53.06M | 692.26K | 32.06M | 0 | 1.64M |
Net Change In Cash | 233.01M | -734K | -5.52M | -17.58M | -27.00M | 43.67M | -5.41M | 29.19M | -1.32M | -186.35K |
Cash at end of period | 247.6M | 14.58M | 15.29M | 22.55M | 37.55M | 62.52M | 22.53M | 30.48M | 1.38M | 2.64M |
| Data source | Data source | Data source | Data source | Data source | Data source |